Who's in and who's out of Goldman Sachs' '10 products that will change the industry'?
This article was originally published in Scrip
Goldman Sachs has updated its annual list of the ten products that it believes can transform the industry, dropping six products from its 2014 list, but keeping the faith in immune-oncology as the largest opportunity for pharma.
You may also be interested in...
A first look at the clinical data for Novavax’s COVID-19 vaccine suggests it can produce strong antibody responses while being well tolerated.
A couple of unexpected events for pimavanserin mean that Acadia will drop its development for major depressive disorder and have to wait a little longer to hear if it can launch the product for dementia-related psychosis, a large potential indication.
The US FDA has given the go-ahead for marketing of ViiV healthcare’s novel HIV drug just as the EMA removes the accelerated assessment status from its application there.